Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Bio-Rad Laboratories Inc. Class A

An announcement from Swedish Orphan Biovitrum AB ( ($SE:SOBI) ) is now available. Sobi reported new pooled Phase 3 data showing that its RNA-target...

Sobi’s Tryngolza cuts pancreatitis risk 85% in severe hypertriglyceridemia trial analysis

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bio-Rad Laboratories (BIO) and Haleon PLC Sponsore...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bio-Rad Laboratories (BIO) and Haleon PLC Sponsored ADR (HLN)

Jefferies analyst Tycho Peterson maintained a Hold rating on Bio-Rad Laboratories today and set a price target of $275.00. According to TipRanks, P...

Jefferies Keeps Their Hold Rating on Bio-Rad Laboratories (BIO)

The oldest rule in investing is simple – buy low and sell high. The challenge, of course, is figuring out which beaten-down stocks are genuinely br...

Insiders Buy the Dip in These 2 Crushed Stocks With Strong Buy Ratings

BridgeBio Pharma received a Hold rating and price target from Citi analyst today. In addition to Citi, BridgeBio Pharma also received a Hold from J...

BridgeBio Pharma (BBIO) Gets a Hold from Citi

Zenas BioPharma, Inc. ($ZBIO) announced an update on their ongoing clinical study. This phase 3 study, titled “A Phase 3, Randomized, Double-blind,...

Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Tough MS Segment

In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Ibio, with a price target of $5.00. Dolezal covers the ...

LifeSci Capital Remains a Buy on Ibio (IBIO)

In a report released today, Roanna Ruiz from Leerink Partners maintained a Buy rating on Ibio, with a price target of $6.00. According to TipRanks,...

Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)

Valion Bio ( ($VBIO) ) has provided an update. On May 14, 2026, Valion Bio reported its first-quarter 2026 results, marking its first full reportin...

Valion Bio Reports Q1 Results, Advances Entolimod Platform

In a report released today, from Oppenheimer maintained a Buy rating on Ibio, with a price target of $6.00. Currently, the analyst consensus on Ibi...

Oppenheimer Reaffirms Their Buy Rating on Ibio (IBIO)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Orchestra BioMed Holdings, with a price target of $10.00. Chen ...

Orchestra BioMed Holdings (OBIO) Receives a Buy from H.C. Wainwright

Analysts have been eager to weigh in on the Healthcare sector with new ratings on LB Pharmaceuticals, Inc. (LBRX), Agios Pharma (AGIO) and Orchestr...

Analysts Offer Insights on Healthcare Companies: LB Pharmaceuticals, Inc. (LBRX), Agios Pharma (AGIO) and Orchestra BioMed Holdings (OBIO)

Orchestra BioMed Holdings (OBIO) Gets a Buy from Piper Sandler

Bioceres Crop Solutions ( ($BIOX) ) has provided an announcement. Bioceres Crop Solutions reported fiscal third-quarter 2026 results on May 11, 202...

Bioceres Crop Solutions Posts 3Q 2026 Loss as Revenues Slide During Post–Pro Farm Restructuring

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cardiol Therapeutics (CRDL) and BridgeBio Pharma (BB...

Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL) and BridgeBio Pharma (BBIO)

An announcement from Harvard Bioscience ( ($HBIO) ) is now available. Harvard Bioscience has outlined a strategic transformation toward translation...

Harvard Bioscience Unveils Strategic Transformation Toward Translational Tools

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, I...

Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amylyx Pharmaceuticals Inc (AMLX), BioAge Labs, Inc. (BIOA) and P...

Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), BioAge Labs, Inc. (BIOA) and Pharvaris (PHVS)

The latest announcement is out from Ibio ( ($IBIO) ). On May 7, 2026, iBio’s board appointed veteran biotech executive Dr. Elizabeth Stoner as a Cl...

iBio Strengthens Board with Appointment of Dr. Stoner

The latest announcement is out from BridgeBio Pharma ( ($BBIO) ). On May 7, 2026, BridgeBio Pharma, Inc. filed an automatic shelf registration stat...

BridgeBio Pharma Launches New $500 Million ATM Program

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arrowhead Pharmaceuticals (ARWR) and Jade Bioscience...

Wall Street Analysts Are Bullish on Top Healthcare Picks

BridgeBio Pharma ( ($BBIO) ) just unveiled an announcement. BridgeBio reported first-quarter 2026 revenue of $194.5 million, largely driven by $180...

BridgeBio Pharma Announces $500 Million Stock Repurchase Program

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tonix Pharma (TNXP), Crescent Biopharma (CBIO) and R...

Analysts Are Bullish on Top Healthcare Stocks: Tonix Pharma (TNXP), Crescent Biopharma (CBIO)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen (AMGN) and BridgeBio Pharma (BBIO) with bullis...

Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), BridgeBio Pharma (BBIO)

Bio-Rad Laboratories (($BIO)) has held its Q1 earnings call. Read on for the main highlights of the call. Bio-Rad Laboratories’ latest earnings cal...

Bio-Rad Laboratories Earnings Call Balances Growth and Strain

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Crescent Biopharma yesterday and set a price target of $30.00. Willey covers the ...

Stifel Nicolaus Keeps Their Buy Rating on Crescent Biopharma (CBIO)

In a report released on April 29, Jon Berggren from Kepler Capital maintained a Buy rating on Swedish Orphan Biovitrum AB, with a price target of S...

Kepler Capital  Reaffirms Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)

Bio-Rad Laboratories ( ($BIO) ) just unveiled an update. Bio-Rad Laboratories reported first-quarter 2026 results on April 30, 2026, showing total ...

Bio-Rad Laboratories Reports Q1 2026 Results, Cuts Outlook

An update from BioVersys AG ( ($CH:BIOV) ) is now available. BioVersys AG reported that shareholders approved all proposals put forward by the Boar...

BioVersys Shareholders Back All Board Proposals, Strengthen Governance at AGM

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY), Crescent Biopharma (CBIO) and ...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Crescent Biopharma (CBIO) and Guardant Health (GH)

In a report released yesterday, Harry Gillis from Berenberg Bank maintained a Buy rating on Swedish Orphan Biovitrum AB, with a price target of SEK...

Swedish Orphan Biovitrum AB (0MTD) Receives a Buy from Berenberg Bank

The latest announcement is out from Swedish Orphan Biovitrum AB ( ($SE:SOBI) ). Sobi reported a strong start to 2026, with first-quarter revenue up...

Sobi posts strong Q1 2026 as launches and pipeline deals power growth

Barclays analyst Eliana Merle maintained a Buy rating on BridgeBio Pharma today and set a price target of $157.00. According to TipRanks, Merle is ...

BridgeBio Pharma (BBIO) Gets a Buy from Barclays

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Qiagen (QGEN) and BridgeBio Pharma (BBIO). Qiagen (QGEN) In a rep...

Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and BridgeBio Pharma (BBIO)

With markets stabilizing and investors moving back to high-growth names, a handful of companies are standing out for their strong momentum, improvi...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BIO	$296.90	+3.18%	454.70K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BIO	$296.90	+3.2%	454.70K
3
4
5
6

BIO

BIO

Get Bio-Rad Laboratories Inc. Class A Data in Excel

Get Bio-Rad Laboratories Inc. Class A Data in Excel